COGT

Cogent Biosciences, Inc. 8-K Summary

Business Context and Reporting Period

Cogent Biosciences, Inc. (COGT) filed a Current Report on Form 8-K on June 11, 2025. The filing discloses the entry into a material definitive agreement to secure non-dilutive financing to support working capital and general business purposes.

Key Financial Metrics and Debt Structure

The Company entered into a Loan and Security Agreement establishing a term loan facility with the following terms:

• Total Facility Size: Up to $400.0 million aggregate principal.
• Initial Funding: $50.0 million funded on the Closing Date (June 11, 2025).
• Interest Rate: 4.75% plus the greater of one-month SOFR or 4.15% per annum.
• Maturity Date: June 1, 2030.
• Repayment Terms: Monthly interest-only payments until June 1, 2028. Principal payments may be deferred until June 1, 2029, subject to conditions. Thereafter, monthly principal and interest payments are required.
• Collateral: Secured by a first-priority security interest in substantially all assets of the Company and its subsidiaries.
• Prepayment: Permitted at any time subject to a premium ranging from 3.0% to 1.0%.

Material Changes and Milestone Tranches

The remaining $350.0 million of the facility is available in tranches contingent upon specific milestones:

1. Tranche 2 ($25.0 million): Subject to positive data from the Phase 2 SUMMIT clinical trial.
2. Tranche 3 ($75.0 million): Subject to positive data from the Phase 3 PEAK clinical trial.
3. Tranche 4 ($50.0 million): Subject to achieving at least $85.0 million in net product revenue on a trailing six-month basis on or prior to June 30, 2027.
4. Tranche 5 ($200.0 million): Subject to mutual agreement between the Company and SLR Investment Corp.

This filing does not provide comparative financial metrics (revenue, profit, cash flow) for the current or prior periods, as it is a current report focused on a specific transaction rather than a periodic financial statement.

Outlook, Risks, and Contingencies

The agreement contains customary covenants and events of default that could trigger immediate repayment of the loans. The Company's ability to access the majority of the committed capital ($350.0 million) is contingent upon achieving clinical and commercial milestones. Failure to meet these milestones would limit the Company's access to the remaining funds under the facility.

Key Facts for Investor Verification

• Verify the specific terms of the "mutual agreement" required for the $200.0 million fifth tranche.
• Monitor the status of the Phase 2 SUMMIT and Phase 3 PEAK clinical trials to assess the likelihood of unlocking the $100.0 million in milestone tranches.
• Review the Company's revenue trajectory to determine feasibility of the $85.0 million trailing six-month revenue target by June 30, 2027.
• Examine the full Loan and Security Agreement (to be filed as an exhibit to the Q2 2025 10-Q) for detailed covenants and default provisions.